Bull&Bear | Metagenomi Surges 125%, Equity Commonwealth Plummets 93% Amid Market Volatility

In the realm of bullish stocks, Metagenomi (MGX) experienced a significant surge, climbing by 125.41% and maintaining a two-day upward streak. The company has projected that its current cash flow is adequate to sustain its operational plans until 2027.

Zeo Energy (ZEO) also saw a substantial increase of 96.30% over two days. This rise was notably influenced by a report filed on Friday, which disclosed a 58.2% stake in Zeo Energy by a major investment firm.

Quantum-Si (QSI) saw its stock price jump by 49.62%, continuing a two-day rally that totaled a 65.83% increase. The company has recently secured a U.S. patent for "Integrated circuits with sequentially coupled charge storage and related technologies."

Procaps (PROC) recorded a 49.01% rise, showing a two-day increase of 51.52%. The group entered into a secured convertible note subscription agreement with a pharmaceutical holding company on November 29.

The RealReal (REAL) advanced by 39.13%, marking a two-day gain of 46.41%. This increase followed an upgrade by a financial institution, which raised its rating to 'overweight.' The bank suggested that due to structural changes, The RealReal's stock might double, prompting a rise in target price from $4.00 to $15.00 per share.

On the bearish side, Equity Commonwealth (EQC) saw a massive drop of 92.64%. The company announced an initial cash liquidation distribution of $19.00 per common share and set the ex-dividend date.

BioAge Labs (BIOA) experienced a steep decline of 76.85% after an investment firm downgraded its rating from ‘buy’ to ‘hold,’ and another firm revised its rating from ‘buy’ to ‘neutral.’ Both firms lowered BioAge Labs' target price to $7.

Graphjet (GTI) fell by 25.63%, following the sale of shares valued at $281,460 by company insiders, as revealed in recent SEC filings.

Agios Pharmaceuticals (AGIO) witnessed a significant drop of 21.09%, setting a historical record for the decrease in its stock value.

Lastly, Revance Therapeutics (RVNC) declined by 20.68%, continuing a three-day downward trend that accumulated to a 27.34% decrease. This downturn was attributed to a reduction of the acquisition price by 53% by Crown Labs.